

# The vitamin D<sub>3</sub> analogue, calcipotriol, induces sphingomyelin hydrolysis in human keratinocytes

Christoph C. Geilen\*, Meryem Bektas, Thomas Wieder, Constantin E. Orfanos

Department of Dermatology, University Medical Center Benjamin Franklin, The Free University of Berlin, Hindenburgdamm 30, D-12200 Berlin, Germany

Received 22 November 1995

**Abstract** The possible role of sphingomyelin cycle for the regulation of cell proliferation was investigated in human keratinocytes. The time-dependent breakdown of sphingomyelin was observed in the immortalized human keratinocyte cell line HaCaT as well as in primary human keratinocytes thereby providing evidence that the sphingomyelin cycle might be of importance in the epidermis. Peak levels of 20–30% sphingomyelin hydrolysis were measured 3 h after treatment of the cells with 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> or with the vitamin D<sub>3</sub> analogue, calcipotriol. The decrease of sphingomyelin upon addition of vitamin D<sub>3</sub> or calcipotriol was accompanied by an approximately 70% increase of ceramide in the cells. The effects of vitamin D<sub>3</sub> and calcipotriol on sphingomyelin breakdown were paralleled by their antiproliferative potency. Furthermore, the cell-permeable ceramide, *N*-acetyl sphingosine, and natural ceramide inhibited cell proliferation of human keratinocytes. The results presented suggest that induction of the sphingomyelin cycle represents one mechanism mediating the therapeutic effect of calcipotriol in treatment of psoriasis.

**Key words:** Calcipotriol; Sphingomyelin hydrolysis; Ceramide; 1 $\alpha$ ,25-Dihydroxyvitamin D<sub>3</sub>; Human keratinocyte; Signal transduction; Cell proliferation; Psoriasis

## 1. Introduction

The sphingomyelin (SM) cycle has been initially identified in HL-60 human leukemia cells as a new cellular signalling pathway in response to vitamin D<sub>3</sub> [1]. It has been shown that a time-dependent and reversible hydrolysis of SM occurs via activation of a sphingomyelinase generating ceramide [2]. Subsequently, the SM cycle is completed by the transfer of a choline head group from phosphatidylcholine to ceramide [3]. Up to now, several other agonists of the SM cycle have been described, including tumor necrosis factor  $\alpha$  (TNF $\alpha$ ),  $\gamma$ -interferon, dexamethasone, interleukin-1, nerve growth factor (NGF), complement and brefeldin A (for review, see [4,5]). It has been implicated that the SM cycle mediates the effects of these agonists finally leading to terminal differentiation or

apoptosis [6,7]. Using cell-permeable ceramide analogues, it was possible to mimic the effects of several inducers of SM hydrolysis on cell proliferation and differentiation [8].

Psoriasis is a disease of the skin which is characterized by an enormous hyperproliferation of keratinocytes and the topical treatment with antiproliferative agents represents a classical concept of therapy [9]. Calcipotriol (MC 903) is a vitamin D<sub>3</sub> analogue which has been found to potently induce cell differentiation and inhibit cell proliferation cells possessing the receptor for 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> by an unknown mechanism [10,11]. Furthermore, topical treatment of psoriasis with calcipotriol has been shown to constitute an effective and potent therapy for this skin disease [12]. Therefore, the elucidation of the mechanism underlying the therapeutic effect of calcipotriol is of great interest and might lead to the development of new drugs.

In the present study, the existence of a 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> inducible SM cycle was demonstrated in human keratinocytes. Additionally, the vitamin D<sub>3</sub> analogue, calcipotriol, was found to induce the hydrolysis of 20–30% of total cellular SM and to increase the formation of ceramide in a time-dependent and reversible manner, with maximal activity after 3 h. 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> as well as calcipotriol inhibited the proliferation of keratinocytes and HaCaT cells and their antiproliferative effects were mimicked by *N*-acetyl sphingosine (C<sub>2</sub>-ceramide) and natural ceramide. Hence, the SM cycle is discussed as a possible mechanism underlying the antiproliferative effect of calcipotriol in psoriasis.

## 2. Materials and methods

### 2.1. Materials

*Streptomyces* sp. sphingomyelase, dodecane and ceramide (from bovine brain SM or cerebroside) were purchased from Sigma (München, Germany). Solvents and reagents (reagent grade) were obtained from Merck (Darmstadt, Germany) and Fluka (Neu-Ulm, Germany). Triton X-100 was purchased from Aldrich (Steinheim, Germany). [*methyl*-<sup>3</sup>H]Choline chloride (2.8–3.1 TBq/mmol), [*N-methyl*-<sup>14</sup>C]SM (2.07 GBq/mmol), 1-3-phosphatidyl-*[N-methyl*-<sup>3</sup>H]choline, 1,2-dipalmitoyl (2.44 TBq/mmol) and L-<sup>3</sup>[<sup>3</sup>H]serine (1.11 TBq/mmol) were from Amersham (Braunschweig, Germany). *N*-Acetyl sphingosine (C<sub>2</sub>-ceramide) was from Alexis (Grünberg, Germany). 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> and calcipotriol (MC 903) were a gift from Dr. L. Binderup (Leo Pharmaceutical Products; Copenhagen, Denmark). For quantification of radioactivity a Berthold (Wildbad, Germany) LB 2821 HR thin-layer chromatography scanner was used.

### 2.2. Cell culture

HaCaT cells [13] were grown in RPMI medium supplemented with 10% heat-inactivated fetal calf serum, 0.35 g/l glutamine, 100 000 IU/l penicillin and 0.1 g/l streptomycin in plastic culture dishes (Nunc; Wiesbaden, Germany). Media and culture reagents were obtained from Gibco (Karlsruhe, Germany). Penicillin and streptomycin were from Boehringer (Mannheim, Germany). Human keratinocytes were pre-

\*Corresponding author. Fax: (49) (30) 8445 4141.

**Abbreviations:** C<sub>2</sub>-ceramide, *N*-acetyl sphingosine; cpm, counts per minute; HaCaT, immortalized human keratinocyte cell line; HL-60, leukemia cell line; KBM, keratinocyte basal medium; KGM, keratinocyte growth medium; MCDB, cell culture media designed for serum-free growth of specific cell types; MUH, 4-methylumbelliferyl heptanoate; NGF, nerve growth factor; PBS, phosphate-buffered saline; RPMI, Roswell Park Memorial Institute; SM, sphingomyelin; TNF $\alpha$ , tumor necrosis factor  $\alpha$ .

pared from human forskin as described recently [14] and cultured in keratinocyte growth medium (KGM). KGM was prepared from keratinocyte basal medium (KBM) by addition of 10 ng/ml epidermal growth factor, 5 µg/ml insulin, 0.5 µM hydrocortisone, 50 µg/ml bovine pituitary extract, 100 µg/ml penicillin/streptomycin, and 2.5 µg/ml fungizone. KBM consisted of MCDB 153 medium as described [15] which was supplemented with 100 µM ethanolamine, 100 µM phosphoethanolamine, 240 µM histidine, 750 µM isoleucine, 90 µM methionine, 90 µM phenylalanine, 45 µM tryptophan, 75 µM tyrosine and 150 µM CaCl<sub>2</sub>. KBM and supplements were purchased from Clonetics (San Diego, CA, USA). 1α,25-dihydroxyvitamin D<sub>3</sub> and calcipotriol were diluted into KBM or KGM as described above from 10 µM stock ethanol solutions. Ceramide was first dissolved in ethanol/dodecane (98:2, v/v) at a concentration of 177 µM as described [16]. The solution was then added to KGM and sonicated for 30 min. C<sub>2</sub>-ceramide was diluted into KGM from a 30 mM stock dimethyl sulphoxide solution. Ethanol, ethanol/dodecane (98:2, v/v) and dimethyl sulphoxide (vehicles) were added to controls and were present at 1%, 0.56% and 0.1%, respectively. 0.1% dimethyl sulphoxide did not significantly reduce the proliferation rate of human keratinocytes (98% of controls). The same was true for 1% ethanol and 0.56% ethanol/dodecane (98:2, v/v).

### 2.3. Choline labelling of cells

For choline labelling of HaCaT cells and human keratinocytes, medium was removed and pulse medium (KGM containing  $3.7 \times 10^4$  Bq/ml [*methyl*-<sup>3</sup>H]choline) was added. After incubation for 72 h, cells were washed twice with phosphate-buffered saline (PBS) and then treated with 100 nM 1α,25-dihydroxyvitamin D<sub>3</sub> or 100 nM calcipotriol in KBM for different time periods. Cells were harvested in 400 µl ice-cold PBS by use of a cell lifter (Costar; Cambridge, MA, USA). After freeze-drying of the cells, lipids were extracted by a modified method of Bligh and Dyer [17] as described [18]. Total lipid extracts were dried under a stream of nitrogen and stored at -20°C.

### 2.4. Sphingomyelin quantitation

SM was quantified using bacterial sphingomyelinase to release [<sup>3</sup>H]phosphocholine as described recently [19]. Briefly, the total lipid extracts were resuspended in 100 µl of assay buffer (100 mM Tris-HCl, pH 7.4, 6 mM MgCl<sub>2</sub>, 0.1% Triton X-100). The samples were sonicated for 5 min and 1 unit/ml sphingomyelinase from *Streptomyces* sp. was added. After incubation at 37°C for 2 h, the reaction was stopped by addition of 1 ml chloroform/methanol (2:1, v/v) and the liberated [<sup>3</sup>H]phosphocholine was recovered with the aqueous phase of a Folch extraction [20]. Phase separation was completed by addition of 100 µl water and the aqueous phase was taken for scintillation counting. The radioactivity of the aqueous phase normally reached 10,000 cpm and the radioactivity in control samples was set as 100%. Subsequently, SM in the samples of calcipotriol or 1α,25-dihydroxyvitamin D<sub>3</sub>-treated cells was calculated as % of control. The assay conditions described above were verified using [*methyl*-<sup>14</sup>C]SM and [*methyl*-<sup>3</sup>H]phosphatidylcholine. As shown in Table 1, maximal SM hydrolysis (> 98%) without accompanying phosphatidylcholine hydrolysis (< 5%) was observed.

Furthermore, SM was also determined by a thin-layer chromatography method. Lipids were spotted on silica gel 60 high-performance thin-layer chromatography plates and plates were developed in chloroform/methanol/triethyl-amine/water (30:35:34:8, by vol). Radioactivity

was quantified by radioscanning. SM and phosphatidylcholine were identified by calibrating the scanner with known standards. A comparison of the thin-layer chromatography method with the sphingomyelinase method demonstrated that the methods gave identical results (23% SM-hydrolysis as compared with control after 60 min of stimulation with TNFα).

### 2.5. Determination of cellular ceramide

The formation of cellular ceramide upon addition of 1α,25-dihydroxyvitamin D<sub>3</sub> or calcipotriol was determined as described [21]. Briefly, subconfluent cells were radiolabelled by the addition of L-[<sup>3</sup>H]serine (2 µCi/ml) to serine-free Minimal Essential Medium (Gibco; Karlsruhe, Germany) containing 5% heat-inactivated fetal calf serum for 24 h. The confluent cells were washed twice with PBS and incubated for 5 h in KGM containing unlabelled serine (5 mM). The cells were washed as before and then treated with 100 nM 1α,25-dihydroxyvitamin D<sub>3</sub> or 100 nM calcipotriol in KBM for different time periods. The medium was removed, and the cells were precipitated in 0.5 ml methanol. Lipids were extracted by addition of 0.25 ml chloroform and incubation for 1 h followed by addition of 0.75 ml chloroform and incubation for a further 30 min. The phases were separated by the addition of 0.75 ml water and the organic phase was removed and dried under a stream of nitrogen. Lipids were solubilized in chloroform/methanol (2:1, v/v), separated by high-performance thin-layer chromatography using the solvent system chloroform/methanol (9:1, v/v), and radioactivity was quantified by radioscanning. Ceramide was identified by calibrating the scanner with radiolabelled ceramide which was prepared by incubation of serine-labelled cells with 0.1 unit/ml sphingomyelinase. The ceramide-bound radioactivity of control samples at time point 0 was 0.66% of total radioactivity. Total radioactivity in the samples normally reached 50,000 cpm. The ceramide-bound radioactivity of control samples was set as 100% and ceramide in the samples of 1α,25-dihydroxyvitamin D<sub>3</sub> or calcipotriol-treated cells was calculated as % of control.

### 2.6. Cell proliferation assays

Human keratinocytes and HaCaT cells were seeded in 96-multiwell plastic culture dishes with a density of  $5 \times 10^3$  cells/cm<sup>2</sup> and treated with different concentrations of 1α,25-dihydroxyvitamin D<sub>3</sub>, calcipotriol, natural ceramide or C<sub>2</sub>-ceramide in KGM. After incubation for 24–72 h, the cells were washed twice with PBS and cell proliferation was determined by the MTT fluorescence assay using 4-methylumbelliferyl heptanoate (Serva, Heidelberg, Germany) as described recently [22]. The absolute fluorescence units of control cells were set as 100% and the proliferation rate of treated cells was calculated as % of control. Additionally, cell proliferation was determined by the crystal violet assay as described in detail [23]. Both assays gave similar results.

### 2.7. Other procedures

Statistical comparisons were made in these studies with Student's *t*-test.

## 3. Results and discussion

### 3.1. Calcipotriol time-dependently activates sphingomyelin hydrolysis

In keratinocytes, the existence of the SM cycle has not been

Table 1  
Distribution of radioactivity between the aqueous and organic phases after sphingomyelinase treatment

Sample	Radioactivity in the aqueous phase (% of total cpm)	Radioactivity in the organic phase (% of total cpm)
[ <i>methyl</i> - <sup>14</sup> C]SM + enzyme	98.4	1.6
[ <i>methyl</i> - <sup>14</sup> C]SM – enzyme	0.7	99.3
[ <i>methyl</i> - <sup>3</sup> H]phosphatidylcholine + enzyme	4.2	95.8
[ <i>methyl</i> - <sup>3</sup> H]phosphatidylcholine – enzyme	1.3	98.7

Trace-amounts of [*methyl*-<sup>14</sup>C]SM (44,000 dpm) or [*methyl*-<sup>3</sup>H]phosphatidylcholine (440,000 dpm) were added to a total lipid extract from HaCaT cells. Then, sphingomyelinase assays were performed as described in section 2 and 400 µl of the aqueous phases and 800 µl of the organic phases were taken for scintillation counting. Values are given as % of total radioactivity and represent the mean of two determinations with an error less than 1%. The experiment was repeated with purified SM and purified phosphatidylcholine and similar results were obtained.

demonstrated yet. We therefore tested the known inducer of SM hydrolysis,  $1\alpha,25$ -dihydroxyvitamin  $D_3$ , in human keratinocytes and in the immortalized human keratinocyte cell line HaCaT. As expected, a time-dependent effect of  $1\alpha,25$ -dihydroxyvitamin  $D_3$  on SM hydrolysis occurred in HaCaT cells (Fig. 1A). The hydrolysis of approximately 25% of total cellular SM was observed after 3 h of  $1\alpha,25$ -dihydroxyvitamin  $D_3$  treatment and SM levels returned to control levels by 6 h. Similar results were obtained in primary keratinocytes (data not shown). The amount of hydrolyzed SM and the time course of SM hydrolysis are in accordance with results obtained in the leukemic cell line HL-60 [1].  $TNF\alpha$ , another well known inducer of the SM cycle [19,24], also activated SM hydrolysis in keratinocytes and HaCaT cells (data not shown). Thus, our results provide strong experimental evidence that the agonist-stimulated hydrolysis of SM represents an operative signal transduction pathway in keratinocytes. This might be of future interest since both SM and sphingomyelinase are present in the epidermis [25,26] and the importance of ceramides in the skin barrier system has been discussed [27].

In another set of experiments, we investigated the effects of the vitamin  $D_3$  analogue, calcipotriol, on SM hydrolysis. As shown in Fig. 1B, incubation of HaCaT cells with 100 nM calcipotriol led to the time-dependent hydrolysis of SM. Maximal effects of approximately 30% SM hydrolysis were observed 3 h after treatment with calcipotriol and the time course of the calcipotriol effect resembled the vitamin  $D_3$  effect described in the previous paragraph. Furthermore, nearly the same effects of calcipotriol were observed in primary keratinocytes (data not shown). The known activators of the SM cycle may be categorized by the temporal nature of their activation. Early activators, such as  $TNF\alpha$  and interleukin-1, cause SM hydrolysis within 15–30 min whereas late activators, such as vitamin  $D_3$  and  $\gamma$ -interferon, show stimulation of SM hydrolysis after 2 h




Fig. 1. Time-dependent hydrolysis of sphingomyelin after  $1\alpha,25$ -dihydroxyvitamin  $D_3$  or calcipotriol treatment of HaCaT cells. Subconfluent HaCaT cells were labelled for 72 h with pulse medium containing  $3.7 \times 10^4$  Bq/ml [ $^3H$ ]choline. Pulse medium was removed and the cells were treated with 100 nM  $1\alpha,25$ -dihydroxyvitamin  $D_3$  (A) or calcipotriol (B). Control media contained 1% ethanol. After different incubation times as indicated in the figure, the cells were harvested and SM was quantitated as described in section 2. Values represent the mean of three experiments and the standard deviation is shown as a vertical bar. \*Significantly different from controls at  $P < 0.05$ . \*\*Significantly different from controls at  $P < 0.02$ .




Fig. 2. Time-dependent formation of ceramide after  $1\alpha,25$ -dihydroxyvitamin  $D_3$  or calcipotriol treatment of HaCaT cells. Subconfluent HaCaT cells were labelled for 24 h with serine-free medium containing  $7.4 \times 10^4$  Bq/ml L-[ $^3H$ ]serine. Pulse medium was removed and the cells were incubated for 5 h with KGM containing 5 mM unlabelled serine. Then, the cells were treated with 100 nM  $1\alpha,25$ -dihydroxyvitamin  $D_3$  (A) or calcipotriol (B). Control media contained 1% ethanol. After different incubation times as indicated in the figure, the cells were harvested and cellular ceramide was quantitated as described in section 2. Values represent the mean of three experiments and the standard deviation is shown as a vertical bar. \*Significantly different from controls at  $P < 0.02$ . \*\*Significantly different from controls at  $P < 0.01$ .

of treatment [3]. From the results obtained we suggest that calcipotriol is a late inducer of the SM cycle.

### 3.2. Calcipotriol time-dependently induces formation of ceramide

It has been shown that treatment of HL-60 cells with vitamin  $D_3$  resulted in an increase of cellular ceramide with peak levels after 2 h [1]. To demonstrate that vitamin  $D_3$  as well as calcipotriol not only activated SM hydrolysis but at the same time induced the formation of cellular ceramide we metabolically labelled the lipid backbone of SM by addition of L-[ $^3H$ ]serine to the medium of the cells. When keratinocytes (data not shown) or HaCaT cells were treated with either vitamin  $D_3$  (Fig. 2A) or calcipotriol (Fig. 2B) an approximately 70% increase of cellular ceramide was observed after 3 h and ceramide returned to base-line levels by 4–6 h. The time-dependent formation of ceramide is in accordance with the time-course of SM hydrolysis thereby confirming the metabolic pathway involved in SM hydrolysis which has been characterized in HL-60 cells [1].

### 3.3. Antiproliferative effects of calcipotriol, $1\alpha,25$ -dihydroxyvitamin $D_3$ , natural ceramide and $C_2$ -ceramide on human keratinocytes and HaCaT cells

To investigate the antiproliferative effect of calcipotriol in comparison with the effect of  $1\alpha,25$ -dihydroxyvitamin  $D_3$ , keratinocytes and HaCaT cells were incubated with different amounts of both substances and the concentration-dependent effects on cell proliferation were measured. As shown in Fig. 3A, keratinocytes were more sensitive to incubation with low concentrations ( $c \leq 100$  nM) of calcipotriol or  $1\alpha,25$ -dihydroxyvitamin  $D_3$  as compared with HaCaT cells and cell prolif-




Fig. 3. Antiproliferative effects of  $1\alpha,25$ -dihydroxyvitamin  $D_3$  and calcipotriol on human keratinocytes and HaCaT cells.  $5 \times 10^3$  keratinocytes/cm<sup>2</sup> (A) and  $5 \times 10^3$  HaCaT cells/cm<sup>2</sup> (B) were treated with different concentrations of  $1\alpha,25$ -dihydroxyvitamin  $D_3$  (●) or calcipotriol (○). Control media contained 1% ethanol. After 48 h (HaCaT cells) and 72 h (keratinocytes), cell proliferation was determined by the MUH fluorescence assay as described in section 2. Values represent the mean of four experiments and the standard deviation is shown as a vertical bar. \*Significantly different from controls at  $P < 0.02$ . \*\*Significantly different from controls at  $P < 0.01$ . \*\*\*Significantly different from controls at  $P < 0.001$ .

eration was inhibited by about 40% in the presence of 100 nM calcipotriol or  $1\alpha,25$ -dihydroxyvitamin  $D_3$ . However, significant antiproliferative effects of both compounds were also observed in HaCaT cells at higher concentrations (Fig. 3B).

There have been a lot of implications in the literature that the SM cycle plays an important role in the negative regulation of cell proliferation and it has been shown that inducers of SM hydrolysis, such as vitamin  $D_3$  and  $TNF\alpha$ , caused growth inhibition of HL-60 cells [28] and human keratinocytes [29]. Furthermore, 4 days after addition of sphingomyelinase to the culture medium of HL-60 cells a decrease in cell proliferation was observed [1] suggesting that SM breakdown and increased levels of ceramides are responsible for the antiproliferative effect. Hence, we used the cell-permeable ceramide, acetylsphingosine ( $C_2$ -ceramide), and natural ceramide in our experimental system.  $C_2$ -ceramide inhibited cell proliferation of keratinocytes (data not shown) and HaCaT cells (Fig. 4) in the low  $\mu$ molar range thereby confirming the results from another laboratory [30]. By using conditions which allowed ceramide penetration into cells [16] we could demonstrate that natural ceramide derived from sphingomyelin (ceramide III) or cerebrosid (ceramide IV) inhibited proliferation of HaCaT cells by 21% and 40%, respectively (Fig. 4).

In conclusion, we provide evidence that the SM cycle, a signalling pathway originally described in HL-60 cells, is also found in the immortalized human keratinocyte cell line HaCaT and in human keratinocytes. In addition to the known inducers of SM hydrolysis,  $1\alpha,25$ -dihydroxyvitamin  $D_3$  and  $TNF\alpha$ , both cell types responded to the antiproliferative, synthetic vitamin  $D_3$  analogue, calcipotriol. Acetylsphingosine, a cell-permeable, short chain ceramide which is similar to the naturally occurring breakdown product of SM hydrolysis, mimicked the effects of calcipotriol and  $1\alpha,25$ -dihydroxyvitamin  $D_3$  on cell proliferation. Therefore, we suggest that the induction of the SM cycle is one possible mechanism underlying the antiproliferative




Fig. 4. Antiproliferative effects of  $C_2$ -ceramide and natural ceramide on HaCaT cells.  $5 \times 10^3$  HaCaT cells/cm<sup>2</sup> were treated with different concentrations of  $C_2$ -ceramide or with different concentrations of natural ceramide. Control media contained 0.1% dimethyl sulphoxide or 0.56% ethanol/dodecane (98:2, v/v). After 24 h, cell proliferation was determined as described in section 2. Values represent the mean of four experiments and the standard deviation is shown as a vertical bar. \*Significantly different from controls at  $P < 0.05$ . \*\*Significantly different from controls at  $P < 0.01$ . \*\*\*Significantly different from controls at  $P < 0.001$ .

effect of the non-calcemic vitamin D<sub>3</sub> analogue, calcipotriol, which is used in the topical treatment of psoriasis.

**Acknowledgements:** We thank Mrs. M. Hoffmann for excellent technical assistance. HaCaT cells were a gift from Dr. N.E. Fusenig (Deutsches Krebsforschungszentrum, Heidelberg, Germany). 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> and calcipotriol (MC 903) were a gift from Dr. L. Binderup (Leo Pharmaceutical Products; Copenhagen, Denmark). The work was supported by research grants from the University Medical Center Benjamin Franklin and the Berliner Krebsgesellschaft.

## References

- [1] Okazaki, T., Bell, R.M. and Hannun, Y.A. (1989) *J. Biol. Chem.* 264, 19076–19080.
- [2] Okazaki, T., Bielawska, A., Bell, R.M. and Hannun, Y.A. (1990) *J. Biol. Chem.* 265, 15823–15831.
- [3] Hannun, Y.A. and Linardic, C.M. (1993) *Biochim. Biophys. Acta* 1154, 223–236.
- [4] Hannun, Y.A. (1994) *J. Biol. Chem.* 269, 3125–3128.
- [5] Hannun, Y.A. and Bell, R.M. (1989) *Science* 243, 500–507.
- [6] Obeid, L.M., Linardic, C.M., Karolak, L.A. and Hannun, Y.A. (1993) *Science* 259, 1769–1771.
- [7] Jarvis, W.D., Kolesnick, R.N., Fornari, F.A., Traylor, R.S., Gerwitz, D.A. and Grant, S. (1994) *Proc. Natl. Acad. Sci. USA* 91, 73–77.
- [8] Bielawska, A., Linardic, C.M. and Hannun, Y.A. (1992) *J. Biol. Chem.* 267, 18493–18497.
- [9] Christophers, E. and Krüger, G.G. (1987) in: *Dermatology in General Medicine* (Fitzpatrick, T.D., Eisen, A.Z., Wolff, K. and Freedberg, I.M., Eds.) McGraw-Hill, New York, pp. 461–491.
- [10] Binderup, L. and Bramm, E. (1988) *Biochem. Pharmacol.* 37, 889–895.
- [11] Kragballe, K. and Wildfang, I.L. (1989) *Skin Pharmacol.* 2, 44–45.
- [12] Kragballe, K., Beck, H.I. and Sogaard, H. (1988) *Br. J. Dermatol.* 119, 223–230.
- [13] Boukamp, P., Petrussevska, R.T., Breitkreutz, D., Hornung, J., Markham, A. and Fusenig, N.E. (1988) *J. Cell Biol.* 106, 761–771.
- [14] Stadler, R., Müller, R. and Orfanos, C.E. (1986) *Br. J. Dermatol.* 114, 273–277.
- [15] Boyce, S.T. and Ham, R.G. (1983) *J. Invest. Dermatol.* 81, 33–40.
- [16] Ji, L., Zhang, G., Uematsu, S., Akahori, Y. and Hirabayashi, Y. (1995) *FEBS Lett.* 358, 211–214.
- [17] Bligh, E.G. and Dyer, W.J. (1959) *Can. J. Biochem. Physiol.* 37, 911–917.
- [18] Haase, R., Wieder, Th., Geilen, C.C. and Reutter, W. (1991) *FEBS Lett.* 288, 129–132.
- [19] Jayadev, S., Linardic, C.M. and Hannun, Y.A. (1994) *J. Biol. Chem.* 269, 5757–5763.
- [20] Folch, J., Lees, M. and Sloane, G.H.S. (1957) *J. Biol. Chem.* 226, 497–509.
- [21] Jones, M.J. and Murray, A.W. (1995) *J. Biol. Chem.* 270, 5007–5013.
- [22] Detmar, M., Geilen, C.C., Wieder, Th., Orfanos, C.E. and Reutter, W. (1994) *J. Invest. Dermatol.* 102, 490–494.
- [23] Geilen, C.C., Haase, R., Buchner, K., Wieder, Th., Hucho, F. and Reutter, W. (1991) *Eur. J. Cancer* 27, 1650–1653.
- [24] Kim, M.-Y., Linardic, C., Obeid, L. and Hannun, Y. (1991) *J. Biol. Chem.* 266, 484–489.
- [25] Yardley, H.J. and Summerly, R. (1981) *Pharmacol. Ther.* 13, 357–383.
- [26] Bowser, P.A. and Gray, G.M. (1978) *J. Invest. Dermatol.* 70, 331–335.
- [27] Gray, G.M. and White, R.J. (1978) *J. Invest. Dermatol.* 70, 336–341.
- [28] Tanaka, H., Abe, E. and Miyaura, C. (1982) *Biochem. J.* 204, 713–719.
- [29] Detmar, M. and Orfanos, C.E. (1990) *Arch. Dermatol. Res.* 282, 238–245.
- [30] Wakita, H., Tokura, Y., Yagi, H., Nishimura, K., Furukawa, F. and Takigawa, M. (1994) *Arch. Dermatol. Res.* 286, 350–354.